NCT04267848 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04267848
Title	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST